A state-of-the-art review on LSD1 and its inhibitors in breast cancer: Molecular mechanisms and therapeutic significance

Guan‐Jun Yang, Yanjun Liu, Lijian Ding, Tao Fan, Minghui Zhu, Zhen-Yuan Shi, Juan-Ming Wen, Meng-Yao Niu, Li Xiang, Zhan-Song Xu, Wan‐Jia Qin, Chen-Jie Fei, Jiong ChenFrontiers in Pharmacology 2022 · DOI

Abstract

Breast cancer (BC) is a kind of malignant cancer in women, and it has become the most diagnosed cancer worldwide since 2020. Histone methylation is a common biological epigenetic modification mediating varieties of physiological and pathological processes. Lysine-specific demethylase 1 (LSD1), a first identified histone demethylase, mediates the removal of methyl groups from histones H3K4me1/2 and H3K9me1/2 and plays a crucial role in varieties of cancer progression. It is also specifically amplified in breast cancer and contributes to BC tumorigenesis and drug resistance via both demethylase and non-demethylase manners. This review provides insight into the overview structure of LSD1, summarizes its action mechanisms in BC, describes the therapeutic potential of LSD1 inhibitors in BC, and prospects the current opportunities and challenges of targeting LSD1 for BC therapy.

Introduction

Breast cancer remains the most frequently diagnosed cancer globally, with drug resistance and metastasis serving as the primary drivers of mortality. Traditional therapies often fail because cancer cells "reprogram" their gene expression to survive. Lysine-specific demethylase 1 (LSD1) is a central player in this reprogramming. As the first identified histone demethylase, it was originally known for removing methyl groups from H3K4 and H3K9. However, researchers have found that LSD1 is significantly overexpressed in BC and acts as a "molecular switch" that promotes tumor growth, helps cancer cells evade the immune system, and induces resistance to chemotherapy and hormone therapy.

Structural and Functional Mechanisms of LSD1

LSD1 is a complex enzyme characterized by three primary structural domains: the SWIRM domain, the Tower domain (TD), and the Amine Oxidase-like Domain (AOD). The AOD contains the catalytic center, while the Tower domain serves as a critical scaffold for protein-protein interactions, such as binding with the CoREST complex.

Figure 1: Structural domains and transcriptional regulatory mechanisms of LSD1. (A) Linear distribution of domains. (B) 3D overview structure. (C) LSD1-mediated transcriptional activation and suppression based on histone methylation context.

LSD1 functions as a protean regulator depending on its molecular context. When it demethylates H3K4me1/2, it typically acts as a transcriptional repressor, often silencing tumor-suppressor genes. Conversely, when associated with the Estrogen Receptor α (ERα), it can demethylate H3K9me1/2, leading to the activation of oncogenic pathways. Beyond its enzymatic activity, LSD1 acts as a "moonlighting" protein, providing a physical scaffold for larger protein complexes that drive cancer progression independently of demethylation.

Furthermore, LSD1 plays a critical role in the tumor microenvironment. It helps tumors stay "cold" by suppressing the infiltration of CD8+ T cells. Inhibiting LSD1 can potentially "heat up" these tumors, making them more susceptible to modern immunotherapy.

Therapeutic Landscape: LSD1 Inhibitors

The medicinal chemistry of LSD1 inhibitors has evolved rapidly, moving from repurposed monoamine oxidase (MAO) inhibitors to highly specific, potent compounds. These are generally classified into several categories:

  • Irreversible Inhibitors: Compounds like ORY-1001 (Iadademstat) form covalent bonds with the FAD cofactor. ORY-1001 is particularly potent, with an $IC_{50}$ of 0.012 μM.
  • Reversible Inhibitors: These offer a potentially better safety profile by avoiding permanent enzyme modification. Natural products, such as Salvianolic acid B ($IC_{50} = 0.11 μM$) and flavonoids from Scutellaria baicalensis, have emerged as promising reversible leads.
  • Dual-Targeting Agents: To combat the complexity of BC, researchers are developing "designed multiple ligands." Dual LSD1/HDAC inhibitors, for instance, show superior efficacy in aggressive triple-negative breast cancer (TNBC) by hitting two epigenetic "brakes" simultaneously.

Data suggests that LSD1 inhibition can re-sensitize BC cells to standard treatments like Tamoxifen (hormone therapy) and Paclitaxel (chemotherapy), offering a path to overcome drug resistance.

Future Perspectives and Challenges

While LSD1 inhibition shows great promise, several hurdles remain. Achieving high selectivity for LSD1 over MAO-A/B is critical to avoid neurological side effects. Furthermore, while clinical trials are underway for leukemia and lung cancer, there is a notable lack of clinical trials specifically targeting breast cancer. Many potent in vitro inhibitors also suffer from poor bioavailability or high toxicity in vivo.

The future of LSD1 therapy may lie in PROTACs (Proteolysis Targeting Chimeras). Unlike traditional inhibitors that only block the active site, PROTACs trigger the complete degradation of the LSD1 protein. This approach could neutralize both the enzymatic and the scaffolding functions of LSD1, potentially offering a more comprehensive therapeutic effect in resistant breast cancers.

Summary updated

Abstract

Breast cancer (BC) is a kind of malignant cancer in women, and it has become the most diagnosed cancer worldwide since 2020. Histone methylation is a common biological epigenetic modification mediating varieties of physiological and pathological processes. Lysine-specific demethylase 1 (LSD1), a first identified histone demethylase, mediates the removal of methyl groups from histones H3K4me1/2 and H3K9me1/2 and plays a crucial role in varieties of cancer progression. It is also specifically amplified in breast cancer and contributes to BC tumorigenesis and drug resistance <i>via</i> both demethylase and non-demethylase manners. This review will provide insight into the overview structure of LSD1, summarize its action mechanisms in BC, describe the therapeutic potential of LSD1 inhibitors in BC, and prospect the current opportunities and challenges of targeting LSD1 for BC therapy.
BibTeX
@inproceedings{yang2022state,
  author = {Guan‐Jun Yang and Yanjun Liu and Lijian Ding and Tao Fan and Minghui Zhu and Zhen-Yuan Shi and Juan-Ming Wen and Meng-Yao Niu and Li Xiang and Zhan-Song Xu and Wan‐Jia Qin and Chen-Jie Fei and Jiong Chen},
  title = {{A state-of-the-art review on LSD1 and its inhibitors in breast cancer: Molecular mechanisms and therapeutic significance}},
  booktitle = {Frontiers in Pharmacology},
  year = {2022},
  doi = {10.3389/fphar.2022.989575},
}
Figure